Cargando…
Combining TMZ and SB225002 induces changes of CXCR2 and VEGFR signalling in primary human endothelial cells in vitro
Standard of care therapy for glioblastoma (GBM) consisting of surgical removal, temozolomide (TMZ) and radiotherapy fails to cure the disease and median survival is limited to 15 months. Therapeutic approaches targeting vascular endothelial growth factor (VEGF)-mediated angiogenesis, one of the majo...
Autores principales: | Urbantat, Ruth M., Jelgersma, Claudius, Vajkoczy, Peter, Brandenburg, Susan, Acker, Gueliz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9350968/ https://www.ncbi.nlm.nih.gov/pubmed/35856448 http://dx.doi.org/10.3892/or.2022.8373 |
Ejemplares similares
-
Tumor-Associated Microglia/Macrophages as a Predictor for Survival in Glioblastoma and Temozolomide-Induced Changes in CXCR2 Signaling with New Resistance Overcoming Strategy by Combination Therapy
por: Urbantat, Ruth M., et al.
Publicado: (2021) -
The CXCL2/IL8/CXCR2 Pathway Is Relevant for Brain Tumor Malignancy and Endothelial Cell Function
por: Urbantat, Ruth M., et al.
Publicado: (2021) -
SB225002 inhibits prostate cancer invasion and attenuates the expression of BSP, OPN and MMP-2
por: Xu, Meng, et al.
Publicado: (2018) -
Advances in Chemokine Signaling Pathways as Therapeutic Targets in Glioblastoma
por: Urbantat, Ruth M., et al.
Publicado: (2021) -
Establishment and Validation of CyberKnife Irradiation in a Syngeneic Glioblastoma Mouse Model
por: Jelgersma, Claudius, et al.
Publicado: (2021)